This gem has been languishing, slowly building amazing evidence of extreme efficacy, pretty much under most WS radars. $40 M market cap is truly bizarre, as I have seen totally discredited biotechs, with 1/10 the market potential of ONCS, maintaining market caps of around $100 million.
Feels good to beat the gutterscum manipulators instead of being shaken out.
Something to keep in mind, but this news is over a week old and it sure hasn't seemed to have much of a negative effect.
Tomorrow will tell, but with positive upgrades this could run to $12 easy enough. It is way into overbought area, and with the Europe looking to impose penalties, I wonder how much further this can run on simply losing 'only' .85; at some point they are going to need to make money, and last I checked they are projecting losses for like the next 2 years (if I remember right). Without JASO's hefty cash reserves, I doubt we would have seen such an impressive run today. A long time until Europe makes the final decision on import penalties though, and Germany is pretty serious in their opposition from what I gather.
Lucky for you to have just jumped in on the short side, cause the upgrades could take this to $12 pretty quickly.
What you failed to take into consideration was the already low boo value coupled with the balance sheet of JASO; simply look at their cash my friend.
AHs looks strong, and I am wondering if the upgrades with $12 targets will start tomorrow. If you are only down such a small amount, you might want to just take the loss in case this has legs to $12. OTOH, it is well into overbought territory, but then many of the solars are in similar condition on the RSI. I think CSIQ makes a better short candidate as they don't have such a large cash cushion and no earnings suprises to worry about for awhile. A lot depends on the outcome of the EU solar anti-dumping investigation against China; though apparently this investigation is to take about 15 months, after 9 months they are legally able to apply provisional anti-dumping duties if there is sufficient evidence to warrant it. Looks like Japan is going to fire up their nuclear reactor program again, as it is just deemed to expensive to rely on other sources alone.
Amazingly encouraging results, but the Financial Mess must be made right.....many past sins to be set right. WS wants to be sure this isn't some unrepeatable outlier. This sets the floor at .06 & pretty much provides us a load-the-boat opportunity.
Indeed - imagine were Bernanke to deem the dollars strength simply unacceptable, the inflation rate still too low, and simply announces the Fed will, for an indeterminate length of time, boost their sundry capital injections to say $100 billion p/mo from the current ~$85 billion; S&P likely would explode upwards to 1800 in a flash. Of course UVXY would collapse to somewhere around $4ish
Seems ~ 6 X avg volume could indeed presage a deal - leaks tend to grow as the word spreads; key will be follow thru w/ heavier volume. Honestly though, considering the indications for efficacy to date, the $35 M MC here seems truly bizarre; could be nothing more than a big player or two simply waking up and going #$%$ - buy buy buy!!!
Don't know about 18 month projections, so much can happen in such a long time frame; but ZNGA is definitely headed for $4 in quick fashion, and that is without any positive news catalyst.
Pretty impressive as these viruses have about a 90% kill rate - too bad we are talking pre-clinical with 2 animal models. Still impressive as hell and a huge validation of their DNA vaccine technology - but there is still years to go to prove it safe/effective with humans.
Fun to turn the tables on the bottom dwellers. LOL
Interesting. Appreciate the alert, but I suspect we are very near the finish line now, and then on to commercialization, assuming of course that we can hit that superiority endpoint.
If you like NWBO you should check out IMUC as well. Both low market caps, both using dendritic vaccines for brain cancer, and both with similarly amazing results from earlier small trials. NWBO has just raised money though, and their shares have even dipped a bit below the recent offering price. NWBO is in P3 vs IMUC's P2, and NWBO is running concurrent trials in Europe and the US, which I think is a serious advantage for any small biotech as it leaves them much less at the mercy of the corrupt FDA.
Long both of them, though long IMUC for much longer.
Realistically, this company is an easy easy 10-bagger; with a bit of time and further confirmation of outstanding efficacy you holding a $5 billion investment here.